L-Asparaginase and Venous Thromboembolism in Acute Lymphocytic Leukemia
- 14 August 2015
- journal article
- review article
- Published by Taylor & Francis in Future Oncology
- Vol. 11 (17) , 2459-2470
Abstract
The occurrence of venous thromboembolism (VTE) in acute lymphocytic leukemia patients receiving L-asparaginase therapy may cause significant morbidity, neurological sequela and possibly worse outcomes. The prophylactic use of antithrombin infusion (to keep antithrombin activity >60%) or low molecular weight heparin (LMWH) may reduce the risk of VTE. The decision to continue L-asparaginase therapy after the development of VTE should be based on anticipated benefits, severity of VTE and the ability to continue therapeutic anticoagulation. In patients receiving asparaginase rechallenge, the use of therapeutic LMWH, monitoring of anti-Xa level and antithrombin level are important. Novel oral anticoagulants are not dependent on antithrombin level, hence offer theoretical advantages over LMWH for the prevention and therapy of asparaginase-related VTE.Keywords
This publication has 49 references indexed in Scilit:
- A 50-Year Journey to Cure Childhood Acute Lymphoblastic LeukemiaSeminars in Hematology, 2013
- The coagulopathy and thrombotic risk associated with L-Asparaginase treatment in adults with acute lymphoblastic leukaemiaLeukemia, 2012
- l‐asparaginase loaded red blood cells in refractory or relapsing acute lymphoblastic leukaemia in children and adults: results of the GRASPALL 2005‐01 randomized trialBritish Journal of Haematology, 2011
- Prospective study of hemostatic alterations in children with acute lymphoblastic leukemiaAmerican Journal of Hematology, 2010
- Comparison of low‐molecular‐weight heparin and antithrombin versus antithrombin alone for the prevention of symptomatic venous thromboembolism in children with acute lymphoblastic leukemiaPediatric Blood & Cancer, 2007
- Results of the Dana-Farber Cancer Institute ALL Consortium Protocol 95-01 for children with acute lymphoblastic leukemiaBlood, 2006
- Comparison of the anticoagulant effect of a direct thrombin inhibitor and a low molecular weight heparin in an acquired antithrombin deficiency in children with acute lymphoblastic leukaemia treated with l‐asparaginase: an in vitro studyBritish Journal of Haematology, 2006
- l-Asparaginase-Induced Antithrombin Type I DeficiencyThe American Journal of Pathology, 2006
- Trend to efficacy and safety using antithrombin concentrate in prevention of thrombosis in children receiving l-asparaginase for acute lymphoblastic leukemiaThrombosis and Haemostasis, 2003
- Lack of pathogenetic role of proteins C and S in thrombosis associated with asparaginase-prednisone-vincristine therapy for leukaemiaBritish Journal of Haematology, 1986